Close



Nov 6, 2023 04:01PM
Aug 29, 2023 04:15PM
Aug 7, 2023 04:01PM
Jun 26, 2023 07:04AM
Jun 26, 2023 07:04AM
Jun 7, 2023 06:56AM
Jun 7, 2023 06:55AM FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy
May 8, 2023 04:01PM
Apr 3, 2023 07:00AM
Feb 27, 2023 04:01PM
Nov 7, 2022 04:01PM
Aug 8, 2022 04:01PM
Jun 8, 2022 07:00AM
Apr 20, 2022 07:00AM FibroGen Announces Completion of Patient Enrollment in ZEPHYRUS-1, a Phase 3 Clinical Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis
Nov 9, 2021 04:01PM
Aug 11, 2021 03:27PM
Aug 11, 2021 09:46AM
Aug 11, 2021 07:00AM
Aug 11, 2021 07:00AM
Aug 9, 2021 04:01PM
Jul 16, 2021 11:34AM What Negative Roxadustat FDA AdCom Vote Means for Fibrogen's (FGEN) Stock?
Jul 16, 2021 09:30AM
Jul 16, 2021 03:57AM
Jul 15, 2021 06:34PM
Jul 15, 2021 06:26PM
Jul 13, 2021 12:46PM
Jun 28, 2021 06:32AM
Jun 25, 2021 09:15AM Astellas Receives Positive CHMP Opinion for EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease
Jun 25, 2021 08:58AM
Jun 25, 2021 08:56AM
Jun 25, 2021 08:54AM
May 26, 2021 09:00PM
May 19, 2021 10:00PM
May 13, 2021 10:00PM
May 10, 2021 04:55PM FibroGen (FGEN) Tops Q1 EPS by 9c, Revenues Miss
May 10, 2021 04:01PM
May 6, 2021 09:31PM
May 5, 2021 10:12PM
May 4, 2021 10:04AM
Apr 28, 2021 07:00PM
Apr 26, 2021 02:22PM
Apr 21, 2021 09:00PM Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Champignon Brands, FibroGen, Canaan, and Credit Suisse and Encourages Investors to Contact the Firm
Apr 20, 2021 12:21PM
Apr 15, 2021 07:04AM
Apr 15, 2021 07:00AM
Apr 14, 2021 09:00PM
Apr 14, 2021 08:32PM
Apr 12, 2021 07:00AM
Apr 12, 2021 07:00AM FibroGen Receives Fast Track Designation from the U.S. FDA for Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy
Apr 7, 2021 09:29AM

240,517 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All